Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 19,540 full-time employees. The company went IPO on 2023-05-09. The company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans women’s health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.